SARS-CoV-2 strain-specific anti-spike IgG ELISA utilizing spike protein produced by silkworms.


Journal

Human antibodies
ISSN: 1875-869X
Titre abrégé: Hum Antibodies
Pays: Netherlands
ID NLM: 9711270

Informations de publication

Date de publication:
2023
Historique:
medline: 3 10 2023
pubmed: 17 7 2023
entrez: 17 7 2023
Statut: ppublish

Résumé

A cost-effective and eco-friendly method is needed for the assessment of humoral immunity against SARS-CoV-2 in large populations. We investigated the performance of an ELISA that uses silkworm-produced proteins to quantify the strain-specific anti-Spike IgG (anti-S IgG) titer. The OD values for the anti-His-tag antibody, a standard material of ELISA quantification, were measured. Correlations between the ELISA for each strain and the Abbott SARS-CoV-2 IgG II Quant assay for the wild type were evaluated with serum samples from nine participants with various infection and vaccination statuses. Linear dose-responses were confirmed by high coefficients of determination: 0.994, 0.994, and 0.996 for the wild-type, Delta, and Omicron (BA.1) strain assays, respectively. The coefficient of determination for the wild-type and Delta strain assays was high at 0.959 and 0.892, respectively, while the Omicron strain assay had a relatively low value of 0.563. Booster vaccinees showed similar or higher titers against all strains compared to infected persons without vaccination. The Omicron-infected persons without vaccination had lower antibody titers against wild type than did the vaccinated persons. This study provides data indicating that the ELISA with silkworm-produced proteins makes it possible to discriminate and quantify the strain-specific anti-S IgG antibody induced by vaccination or infection.

Sections du résumé

BACKGROUND BACKGROUND
A cost-effective and eco-friendly method is needed for the assessment of humoral immunity against SARS-CoV-2 in large populations.
OBJECTIVE OBJECTIVE
We investigated the performance of an ELISA that uses silkworm-produced proteins to quantify the strain-specific anti-Spike IgG (anti-S IgG) titer.
METHODS METHODS
The OD values for the anti-His-tag antibody, a standard material of ELISA quantification, were measured. Correlations between the ELISA for each strain and the Abbott SARS-CoV-2 IgG II Quant assay for the wild type were evaluated with serum samples from nine participants with various infection and vaccination statuses.
RESULTS RESULTS
Linear dose-responses were confirmed by high coefficients of determination: 0.994, 0.994, and 0.996 for the wild-type, Delta, and Omicron (BA.1) strain assays, respectively. The coefficient of determination for the wild-type and Delta strain assays was high at 0.959 and 0.892, respectively, while the Omicron strain assay had a relatively low value of 0.563. Booster vaccinees showed similar or higher titers against all strains compared to infected persons without vaccination. The Omicron-infected persons without vaccination had lower antibody titers against wild type than did the vaccinated persons.
CONCLUSIONS CONCLUSIONS
This study provides data indicating that the ELISA with silkworm-produced proteins makes it possible to discriminate and quantify the strain-specific anti-S IgG antibody induced by vaccination or infection.

Identifiants

pubmed: 37458030
pii: HAB230006
doi: 10.3233/HAB-230006
doi:

Substances chimiques

spike protein, SARS-CoV-2 0
Spike Glycoprotein, Coronavirus 0
Antibodies, Viral 0
Immunoglobulin G 0
Antibodies, Neutralizing 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

27-33

Auteurs

Takeyuki Goto (T)

Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences (The First Department of Internal Medicine), Fukuoka, Japan.

Tomoki Sasaki (T)

R&D Department, KAICO Ltd, Fukuoka, Japan.
Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Yong Chong (Y)

Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences (The First Department of Internal Medicine), Fukuoka, Japan.

Masahiro Taniguchi (M)

R&D Department, KAICO Ltd, Fukuoka, Japan.

Jae Man Lee (JM)

Laboratory of Creative Science for Insect Industries Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Akitsu Masuda (A)

Laboratory of Creative Science for Insect Industries Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Takeru Ebihara (T)

Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Kenichiro Shiraishi (K)

Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences (The First Department of Internal Medicine), Fukuoka, Japan.

Naoki Tani (N)

Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences (The First Department of Internal Medicine), Fukuoka, Japan.

Akiko Yonekawa (A)

Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences (The First Department of Internal Medicine), Fukuoka, Japan.

Kei Gondo (K)

COVID-19 Team, Fukuoka City Hospital, Fukuoka, Japan.

Hiroyuki Kuwano (H)

COVID-19 Team, Fukuoka City Hospital, Fukuoka, Japan.

Nobuyuki Shimono (N)

Center for the Study of Global Infection, Kyushu University Hospital, Fukuoka, Japan.

Hideyuki Ikematsu (H)

Ricerca Clinica Co., Fukuoka, Japan.

Koichi Akashi (K)

Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences (The First Department of Internal Medicine), Fukuoka, Japan.

Takahiro Kusakabe (T)

Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH